Mycophenolate mofetil versus cyclosporin A in high risk keratoplasty patients: a prospectively randomised clinical trial

BACKGROUND/AIMS—The requirement for an effective, minimally toxic immunosuppressive agent remains a major obstacle to performing high risk corneal transplantation. Although therapy with cyclosporin A (CSA) allows superior graft survival, its use is limited because of a wide range of side effects. My...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Reis, A., Reinhard, T., Voiculescu, A., Kutkuhn, B., Godehardt, E., Spelsberg, H., Althaus, C., Sundmacher, R.
Format: Artigo
Idioma:Inglês
Publicat: 1999
Matèries:
Original articles - Clinical science
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC1722847/
https://ncbi.nlm.nih.gov/pubmed/10535855
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars